Vivo Capital LLC cut its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 0.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 359,827 shares of the biopharmaceutical company’s stock after selling 1 shares during the period. Dynavax Technologies Corporation makes up 0.9% of Vivo Capital LLC’s portfolio, making the stock its 18th largest position. Vivo Capital LLC’s holdings in Dynavax Technologies Corporation were worth $3,472,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in DVAX. Parametric Portfolio Associates LLC increased its stake in Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock valued at $162,000 after buying an additional 939 shares during the period. Bank of New York Mellon Corp increased its stake in Dynavax Technologies Corporation by 3.9% in the first quarter. Bank of New York Mellon Corp now owns 176,996 shares of the biopharmaceutical company’s stock valued at $1,053,000 after buying an additional 6,623 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Dynavax Technologies Corporation during the first quarter valued at approximately $121,000. Falcon Point Capital LLC increased its stake in Dynavax Technologies Corporation by 57.5% in the first quarter. Falcon Point Capital LLC now owns 117,568 shares of the biopharmaceutical company’s stock valued at $700,000 after buying an additional 42,929 shares during the period. Finally, C WorldWide Group Holding A S increased its stake in Dynavax Technologies Corporation by 8.1% in the first quarter. C WorldWide Group Holding A S now owns 284,082 shares of the biopharmaceutical company’s stock valued at $1,690,000 after buying an additional 21,313 shares during the period. 56.05% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Corporation (DVAX) opened at 16.30 on Friday. The firm’s market capitalization is $892.38 million. The company has a 50 day moving average of $11.71 and a 200 day moving average of $7.12. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $19.60.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.15 million. During the same period last year, the firm posted ($0.75) EPS. Analysts forecast that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Vivo Capital LLC Sells 1 Shares of Dynavax Technologies Corporation (DVAX)” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of U.S. & international copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/08/13/vivo-capital-llc-sells-1-shares-of-dynavax-technologies-corporation-dvax.html.

Several analysts have recently commented on the stock. Cowen and Company reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday. William Blair reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Wednesday. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a report on Friday, August 4th. BidaskClub downgraded shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a report on Monday, July 31st. Finally, Royal Bank Of Canada set a $7.00 price objective on shares of Dynavax Technologies Corporation and gave the company a “hold” rating in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. Dynavax Technologies Corporation currently has an average rating of “Hold” and an average target price of $23.34.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.